From Pandemic Powerhouse to Point-of-Care Pioneer in Mexico

SALT LAKE CITY, UT – June 11, 2026 – Co-Diagnostics, a molecular diagnostics company that became a key player during the COVID-19 pandemic, has anchored its future strategy in Latin America by signing an exclusive distribution agreement in Mexico. The deal is for its next-generation Co-Dx™ PCR Pro® platform, a system designed to bring the power of laboratory-grade diagnostics to the point of care. This move signals a critical intersection of global business strategy and public health innovation, but the ambitious plan to reshape disease detection in one of the region's largest markets hinges on navigating a complex web of international regulatory approvals.

Beyond COVID: A Strategic Pivot to a Diversified Diagnostic Future

The agreement is not with a new entity but an extension and expansion of a highly successful partnership. By granting its longstanding Mexican distributor exclusive rights to the forthcoming PCR Pro platform for five years, Co-Diagnostics is doubling down on a proven relationship. This collaboration has already been immensely fruitful, generating over $18 million in revenue for the Utah-based company since 2020. More strikingly, the partnership was instrumental in the widespread adoption of the company's Logix Smart® COVID-19 test, which, according to the company, comprised more than 50% of all COVID-19 tests used across Mexico through 2021—a testament to the distributor’s logistical prowess and market penetration.

Now, the strategy is evolving. This deal is less about recapturing pandemic-level revenues and more about a fundamental pivot towards a sustainable, diversified future. The Co-Dx™ PCR Pro® is a platform technology, and the company is moving aggressively to populate it with a broad menu of tests that address pressing public health needs beyond COVID-19. As stated by CEO Dwight Egan, "As we prepare for commercialization of the Co-Dx PCR point-of-care platform, we believe this agreement positions us well to support the introduction of a broader menu of point-of-care molecular diagnostics products across Mexico." That menu includes diagnostics for tuberculosis, HPV, mpox, and H5N1 avian flu, along with a recently announced initiative for an Ebola assay. This shift illustrates a forward-thinking adaptation, leveraging the infrastructure and relationships built during a crisis to tackle endemic and emerging infectious diseases.

The Promise of Decentralized Diagnostics for Mexico

Bringing the Co-Dx™ PCR Pro® platform to Mexico represents more than a commercial expansion; it embodies a potential paradigm shift in the nation's public health capabilities. Mexico is not only Latin America's second-largest country by population but also possesses a burgeoning molecular diagnostics market projected by some analysts to grow from over $420 million in 2024 to nearly $1 billion by 2033. The core innovation of the PCR Pro is its aim to democratize polymerase chain reaction (PCR) testing, long considered the gold standard for its accuracy but traditionally confined to centralized laboratories due to cost, complexity, and turnaround time.

The platform is designed to deliver real-time PCR results in approximately 30 minutes, with a user-friendly interface managed via a mobile app. This leap in accessibility could revolutionize disease management, particularly in a country with vast rural areas and communities far from urban lab centers. Rapid, on-site diagnosis enables immediate clinical decisions, facilitates quicker treatment, and helps public health officials track and contain outbreaks with unprecedented speed. While Co-Diagnostics will face stiff competition from established point-of-care systems like Abbott's ID NOW and Cepheid's GeneXpert, it is betting that its platform’s unique combination of ease of use, proprietary Co-Primers™ technology designed to reduce false positives, and a diverse testing portfolio will carve out a significant market share.

Navigating the Regulatory Gauntlet

Despite the strategic foresight and commercial groundwork, a critical asterisk hangs over the entire initiative: the platform is "subject to applicable regulatory review and authorization." The distribution agreement prepares the commercial highway, but the vehicles are not yet street-legal. Before the PCR Pro® can be sold in Mexico, it must clear significant regulatory hurdles, most notably with the U.S. Food and Drug Administration (FDA) and Mexico’s own health authority, COFEPRIS.

The path to approval is rarely straightforward. Co-Diagnostics previously submitted its platform and a COVID-19 test for FDA 510(k) clearance in June 2024, but later withdrew the application following engagement with the agency, a detail noted in company filings. The company is now pursuing alternative regulatory pathways for its tests, including clinical evaluations for an upper respiratory multiplex panel that began in late 2025. In Mexico, the COFEPRIS approval process involves rigorous documentation, quality system audits, and a review that can take anywhere from three months to over a year, depending on the device's risk classification. Securing the distribution deal in advance is a calculated risk, demonstrating confidence to the market while working behind the scenes to navigate the intricate and often unpredictable world of medical device regulation.

A Blueprint for a Broader Latin American Footprint

The agreement in Mexico is best understood as a strategic beachhead for a much larger continental ambition. The Latin American point-of-care diagnostics market is projected to exceed $1.15 billion by 2031, fueled by a growing middle class, improving healthcare infrastructure, and the persistent burden of infectious diseases. The challenges posed by tuberculosis, HPV-related cancers, and other pathogens create a clear and urgent demand for the exact type of accessible, rapid diagnostic solutions Co-Diagnostics aims to provide.

This expansion is not just an opportunity but a strategic imperative. After the boom of the pandemic, Co-Diagnostics has faced financial headwinds, reporting a net loss of $9.1 million on just $0.15 million in revenue in the first quarter of 2026. The company’s survival and long-term growth depend on successfully commercializing its new platform and diversifying its revenue streams. By solidifying its partnership in Mexico, Co-Diagnostics is creating a template for market entry that it can potentially replicate across the region, de-risking the commercial launch phase by leveraging local expertise. This move perfectly illustrates the high-stakes game of post-pandemic innovation, where companies must deftly translate past success into a durable vision for the future.